Laryngeal cancer medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (21 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Laryngeal cancer}} | {{Laryngeal cancer}} | ||
{{CMG}} {{AE}}{{ | {{CMG}} {{AE}}{{OK}} | ||
==Overview== | ==Overview== | ||
The | The [[medical]] therapy combined with [[radiation]] has largely replaced the [[Surgery|surgical]] cure for [[laryngeal cancer]]. However, the treatment truly depends on the stage at the time of [[diagnosis]]. Multiple factors should be taken into account when considering treatment such as [[laryngeal]] preservation, maintaining the [[airway]], s[[Swallowing|wallowing]] and s[[Speech|peech]]. Induction therapy includes three cycles of continuous infusion of [[cisplatin]] (100 mg/m2 on day 1) plus [[fluorouracil]] (1000 mg/m2/day) followed by definitive [[radiation therapy]] in the induction phase and concurrent consists of [[cisplatin]] (100 mg/m2 on days 1, 22, and 43) with [[radiation therapy]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
The | The [[medical]] therapy combined with [[radiation]] has largely replaced the surgical cure for [[laryngeal cancer]]. However, the treatment truly depends on the stage at the time of [[diagnosis]].<ref name="pmid17453448">{{cite journal |vauthors=Tamura Y, Tanaka S, Asato R, Hirano S, Yamashita M, Tamaki H, Ito J |title=Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years |journal=Acta Otolaryngol Suppl |volume= |issue=557 |pages=62–5 |date=February 2007 |pmid=17453448 |doi=10.1080/00016480601067990 |url=}}</ref> Multiple factors should be taken into account when considering treatment: <ref name="pmid19306746">{{cite journal |vauthors=Lefebvre JL, Ang KK |title=Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary |journal=Int. J. Radiat. Oncol. Biol. Phys. |volume=73 |issue=5 |pages=1293–303 |date=April 2009 |pmid=19306746 |doi=10.1016/j.ijrobp.2008.10.047 |url=}}</ref><ref name="pmid19283793">{{cite journal |vauthors=Lefebvre JL, Ang KK |title=Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary |journal=Head Neck |volume=31 |issue=4 |pages=429–41 |date=April 2009 |pmid=19283793 |doi=10.1002/hed.21081 |url=}}</ref> | ||
* [[Laryngeal]] preservation | |||
{| | * Maintaining the [[airway]] | ||
| | * [[Swallowing]] | ||
| | * [[Speech]] | ||
| | |||
| | |||
| | |||
* | |||
=== Chemotherapy: === | |||
: | [[Chemotherapy]] consists of two phases:<ref name="pmid14645636">{{cite journal |vauthors=Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J |title=Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer |journal=N. Engl. J. Med. |volume=349 |issue=22 |pages=2091–8 |date=November 2003 |pmid=14645636 |doi=10.1056/NEJMoa031317 |url=}}</ref><ref name="pmid23182993">{{cite journal |vauthors=Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS |title=Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer |journal=J. Clin. Oncol. |volume=31 |issue=7 |pages=845–52 |date=March 2013 |pmid=23182993 |pmc=3577950 |doi=10.1200/JCO.2012.43.6097 |url=}}</ref> | ||
: | |||
'''Induction''': Three cycles of continuous infusion of [[cisplatin]] (100 mg/m2 on day 1) plus [[fluorouracil]] (1000 mg/m2/day ) followed by definitive [[radiation therapy]] in the induction phase | |||
'''Concurrent:''' [[Cisplatin]] (100 mg/m2 on days 1, 22, and 43) with [[radiation therapy]] | |||
=== '''Radiation therapy''' === | |||
[[Radiotherapy]] can be very helpful in preserving the [[larynx]] and [[voice]]. It has shown similar [[efficacy]] with concomitant [[cisplatin]] as the [[laryngectomy]]-free survival <ref name="pmid23007323">{{cite journal |vauthors=Smee RI, Williams JR, Broadley K, Bridger GP |title=Early glottic carcinoma treated by radiotherapy: defining a population for surgical salvage |journal=Laryngoscope |volume=123 |issue=1 |pages=171–6 |date=January 2013 |pmid=23007323 |doi=10.1002/lary.23663 |url=}}</ref><ref name="pmid8783399">{{cite journal |vauthors=Carl J, Andersen LJ, Pedersen M, Greisen O |title=Prognostic factors of local control after radiotherapy in T1 glottic and supraglottic carcinoma of the larynx |journal=Radiother Oncol |volume=39 |issue=3 |pages=229–33 |date=June 1996 |pmid=8783399 |doi= |url=}}</ref><ref name="pmid20153124">{{cite journal |vauthors=Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM |title=T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy |journal=Int. J. Radiat. Oncol. Biol. Phys. |volume=78 |issue=2 |pages=461–6 |date=October 2010 |pmid=20153124 |doi=10.1016/j.ijrobp.2009.08.066 |url=}}</ref> | |||
: | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
== | |||
== | |||
==References== | ==References== | ||
{{reflist| | {{reflist|1}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
| Line 113: | Line 28: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Otolaryngology]] | |||
Latest revision as of 00:44, 20 March 2019
|
Laryngeal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Laryngeal cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Laryngeal cancer medical therapy |
|
Risk calculators and risk factors for Laryngeal cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
The medical therapy combined with radiation has largely replaced the surgical cure for laryngeal cancer. However, the treatment truly depends on the stage at the time of diagnosis. Multiple factors should be taken into account when considering treatment such as laryngeal preservation, maintaining the airway, swallowing and speech. Induction therapy includes three cycles of continuous infusion of cisplatin (100 mg/m2 on day 1) plus fluorouracil (1000 mg/m2/day) followed by definitive radiation therapy in the induction phase and concurrent consists of cisplatin (100 mg/m2 on days 1, 22, and 43) with radiation therapy.
Medical Therapy
The medical therapy combined with radiation has largely replaced the surgical cure for laryngeal cancer. However, the treatment truly depends on the stage at the time of diagnosis.[1] Multiple factors should be taken into account when considering treatment: [2][3]
- Laryngeal preservation
- Maintaining the airway
- Swallowing
- Speech
Chemotherapy:
Chemotherapy consists of two phases:[4][5]
Induction: Three cycles of continuous infusion of cisplatin (100 mg/m2 on day 1) plus fluorouracil (1000 mg/m2/day ) followed by definitive radiation therapy in the induction phase
Concurrent: Cisplatin (100 mg/m2 on days 1, 22, and 43) with radiation therapy
Radiation therapy
Radiotherapy can be very helpful in preserving the larynx and voice. It has shown similar efficacy with concomitant cisplatin as the laryngectomy-free survival [6][7][8]
References
- ↑ Tamura Y, Tanaka S, Asato R, Hirano S, Yamashita M, Tamaki H, Ito J (February 2007). "Therapeutic outcomes of laryngeal cancer at Kyoto University Hospital for 10 years". Acta Otolaryngol Suppl (557): 62–5. doi:10.1080/00016480601067990. PMID 17453448.
- ↑ Lefebvre JL, Ang KK (April 2009). "Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary". Int. J. Radiat. Oncol. Biol. Phys. 73 (5): 1293–303. doi:10.1016/j.ijrobp.2008.10.047. PMID 19306746.
- ↑ Lefebvre JL, Ang KK (April 2009). "Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary". Head Neck. 31 (4): 429–41. doi:10.1002/hed.21081. PMID 19283793.
- ↑ Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (November 2003). "Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer". N. Engl. J. Med. 349 (22): 2091–8. doi:10.1056/NEJMoa031317. PMID 14645636.
- ↑ Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS (March 2013). "Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer". J. Clin. Oncol. 31 (7): 845–52. doi:10.1200/JCO.2012.43.6097. PMC 3577950. PMID 23182993.
- ↑ Smee RI, Williams JR, Broadley K, Bridger GP (January 2013). "Early glottic carcinoma treated by radiotherapy: defining a population for surgical salvage". Laryngoscope. 123 (1): 171–6. doi:10.1002/lary.23663. PMID 23007323.
- ↑ Carl J, Andersen LJ, Pedersen M, Greisen O (June 1996). "Prognostic factors of local control after radiotherapy in T1 glottic and supraglottic carcinoma of the larynx". Radiother Oncol. 39 (3): 229–33. PMID 8783399.
- ↑ Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM (October 2010). "T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy". Int. J. Radiat. Oncol. Biol. Phys. 78 (2): 461–6. doi:10.1016/j.ijrobp.2009.08.066. PMID 20153124.